leisure time -WSS

leisure time

author：focus 2025-09-27 15:59:03 - browse：37712

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： How state and local governments are sidelining science

WSS

Cancer diagnosis changes perspective doctor, former hospital CEO

Type 2 diabetes prevention programs work at large scale: study

Medical school prerequisites are outdated

What health policies could hitch a ride on a spending bill?

After decades in use, heart stents finally beat placebo

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

focus

leisure time

focus

23andMe had bad news about my health. I wish a person had delivered it

Medical school prerequisites are outdated

Hepatitis C has a cure — but many Americans still lack access to it

A letter from the executive editor: STAT UnitedHealth investigation

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

After affirmative action ruling, medical educators look to 'holistic review'

First transplant of an entire human eye performed

Medical records are filled with copy

Weight loss drugs should be covered by insurers, AMA says

hotspot

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Medical school prerequisites are outdated

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Healthy food access boosts outcomes in two studies

What is STAT's opinion section for?

Experimental asthma app from Apple and Anthem shows promise

explore

entertainment

entertainment

knowledge